Science & Innovation


Volume 5
to find
out more
female scientist

Collaborating to create real impact with tobacco harm reduction

The science and evidence-base to support tobacco harm reduction continues to grow. Recent scientific meetings have provided a much-needed face-to-face opportunity to discuss new data and approaches to assessing and understanding the potential of reduced-risk*† alternative tobacco and nicotine products, as well as learning more about the latest innovations, technologies, and perspectives.

Find out more
male scientist

What’s new in Modern Oral products?

We have completed an innovative study of our Veloi Modern Oral nicotine pouches. The results, which have been published in Biomarkers Journal, provide important new evidence to support the role these pouches can play in Tobacco Harm Reduction.

Find out more
3 glo products

What’s new in Tobacco Heating Products?

We have delivered our biggest clinical study to date — a year-long prospective study of our flagship Tobacco Heating Product (THP), gloTM. The ground-breaking results, which have been published in Internal and Emergency Medicine, provide important new evidence to support’s glo’s potential as a reduced-risk* alternative to cigarettes.

Find out more
a product being tested in a lab

Building the scientific evidence for Vuse

Vaping is a well-established alternative to cigarettes with an established evidence-base accumulated over recent years. However, more is needed and it is important to continue to generate new evidence to support this growing category.

Find out more


This is a report by British American Tobacco p.l.c.; associate companies are excluded. References to ‘British American Tobacco’, ‘BAT’, ‘we’, ‘us’ and ‘our’ when denoting opinion refer to British American Tobacco p.l.c. (the Company, and together with its subsidiaries, the ‘Group’), and when denoting tobacco business activity refer to Group operating companies, collectively or individually as the case may be.

This report contains certain forward-looking statements, including “forward-looking” statements made within the meaning of the US Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or phrases such as “believe,” “anticipate,” “could,” “may,” “would,” “should,” “intend,” “plan,” “potential,” “predict,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy,” “outlook”, “target” and similar expressions. These include statements regarding our intentions, beliefs or current expectations reflecting knowledge and information available at the time of preparation, and concerning our results of operations, financial condition, liquidity, prospects, growth, strategies and the economic and business circumstances occurring from time to time in the countries and markets in which the Company operates, including the projected future financial and operating impacts of the COVID-19 pandemic.

All such forward-looking statements involve estimates and assumptions that are subject to risks, uncertainties and other factors. It is believed that the expectations reflected in this report are reasonable but they may be affected by a wide range of variables that could cause actual results to differ materially from those currently anticipated.

Among the key factors that could cause actual results to differ materially from those projected in the forward looking statements are uncertainties related to the following: the impact of adverse domestic or international legislation and regulation; the inability to develop, commercialise and deliver the Group’s New Categories strategy; the impact of significant increases or structural changes in tobacco, nicotine and New Categories-related taxes; changes or differences in domestic or international economic or political conditions; the impact of serious injury, illness or death in the workplace; adverse decisions by domestic or international regulatory bodies; and the inability to lead the development and roll-out of BAT innovations (New Category products and combustibles), including as a result of unsuccessful research and development or a failure to develop robust scientific risk assessment frameworks.

The forward-looking statements reflect knowledge and information available at the date of preparation of these materials, and the Company undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. Readers are cautioned not to place undue reliance on such forward-looking statements.

The material in this report is provided for the purpose of giving information about the Company to stakeholders only and is not intended for general consumers. The Company, its directors, officers, employees, agents or advisers do not accept or assume responsibility to any other person to whom this material is shown or into whose hands it may come and any such responsibility or liability is expressly disclaimed.

The material in this Report is not provided for product advertising, promotional or marketing purposes. This material does not constitute and should not 
be construed as constituting an offer to sell, or a solicitation of an offer to buy, any of our products. Our products are sold only in compliance with the laws of the particular jurisdictions in which they are sold.

Additional information concerning these and other factors can be found in BAT’s filings with the US Securities and Exchange Commission (“SEC”), including the Annual Report on Form 20-F and Current Reports on Form 6-K, which may be obtained free of charge at the SEC’s website,

Back to top of page